June 17, 2019

Theratechnologies Confirms Decision to Pursue Development of Tesamorelin for NASH in HIV

Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced that it will pursue the development of tesamorelin for the treatment of Non-alcoholic steatohepatitis (“NASH”) in people living with HIV.